Repare Insider Sales Reveal Confidence in Xeno Merger; Investor Implications
Insider sales reveal confidence in Repare’s merger with XenoTherapeutics; investors weigh $2.20 cash per share, contingent value rights, and future oncology prospects.
3 minutes to read